Childhood multiple sclerosis: A review

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 12, Issue 2, 2006, Pages 147-156

  Waldman, Amy ^a   O'Connor, Erin ^a   Tennekoon, Gihan I ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Children; Clinical features; Multiple sclerosis; Pathogenesis; Therapy

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CLADRIBINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; GLATIRAMER; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; INTERLEUKIN 4; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PREDNISONE; RITUXIMAB; SIMVASTATIN; UNINDEXED DRUG; VACCINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGE DISTRIBUTION; ALOPECIA; ANEMIA; ASTHENIA; ATAXIA; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHILDHOOD DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CORDOTOMY; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERTENSION; INFERTILITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER INJURY; LUMBAR PUNCTURE; LYMPHOCYTOPENIA; MCDONALD DIAGNOSTIC CRITERIA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NERVE FIBER; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; ONSET AGE; PANCREATITIS; PARESTHESIA; PATHOGENESIS; PHYSICAL DISABILITY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REHABILITATION; REINFECTION; RELAPSE; REVIEW; RHIZOTOMY; SEIZURE; SENSORY DYSFUNCTION; SPASTICITY; SYMPTOMATOLOGY; TENOTOMY; THORAX PAIN; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING; WEAKNESS; WHITE MATTER;

ANTI-INFLAMMATORY AGENTS; BRAIN; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 33745714342     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20105     Document Type: Review

References (95)

1. Aharoni R, Kayhan B, Eilam R, et al. 2003. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100:14157-14162.
2. Azoulay D, Vachapova V, Shihman B, et al. 2005. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 167:215-218.
3. Banwell B, Reder AT, Krupp L, et al. 2006. Safety and tolerability of interferon β-1b in pediatric multiple sclerosis. Neurology 66:472-476.
4. Barkhof F, Filippi M, Miller DH, et al. 1997. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059-2069.
5. Barkhof F, Hommes O, Scheltens P, et al. 1991. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 41:1219-1222.
6. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55:458-468.
7. Bechtold DA, Kapoor R, Smith KJ. 2004. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607-616.
8. Beck RW. 1988. The Optic Neuritis Treatment Trial. Arch Ophthalmol 106:1051-1053.
9. Beutler E, Sipe J, Romine JS, et al. 1996. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93:1716-1720.
10. Boiko A, Vorobeychik G, Paty D, et al. 2002. Early onset multiple sclerosis: A longitudinal study. Neurology 59:1006-1010.
11. Bourdette DN, Edmonds E, Smith C, et al. 2005. A highly immunogenic trivalent T cell receptor peptide vaccine for MS. Mult Scler 11:552-561.
12. Brass SD, Caramanos Z, Santos C. 2003. Multiple sclerosis and acute disseminated encephalomyelitis in childhood. Pediatr Neurol 29:227-231.
13. Burnham JA, Wright RR, Dreisbach J, et al. 1991. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 41:1349-1354.
14. Canadian Cooperative Multiple Sclerosis Study Group. 1991. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441-446.
15. Chataway J, Feakes R, Coraddu F. 1998. The genetics of multiple sclerosis: Principles, background and updated results of the United Kingdom systematic genome screen. Brain 121:1869-1887.
16. Cohen O, Biran I, Steiner I. 2000. Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural CNS lesions. Arch Neurol 57:553-557.
17. Cole GF, Auchterlonie LA, Best PV. 1995. Very early onset multiple sclerosis. Dev Med Child Neurol 37:667-672.
18. Compston A. 2003. Genetic susceptibility and epidemiology. In: Lazzarini RA, editor. Myelin Biology and Disorders. St. Louis, MO: Elsevier Academic, pp 701-731.
19. Correale J, Lund B, McMillian M. 2000. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 107:130-139.
20. Currier RD, Haerer AF, Meydrech EF. 1993. Low dose oral niethotrexate treatment of multiple sclerosis: A pilot study. J Neurol Neurosurg Psychiatry 56:1217-1218.
21. Dale RC, de Sousa C, Chong WK, et al. 2000. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123:2407-2422.
22. Duquette P, Murray TJ, Pleines J, et al. 1987. Multiple sclerosis in childhood: Clinical profile in 125 patients. Disabil Rehabil 111:359-363.
23. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. 1997. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589-593.
24. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis-The plaque and its pathogenesis. N Engl J Med 354:942-955.
25. Gadoth N. 2003. Multiple sclerosis in children. Brain Dev 25:229-232.
26. Gall JC, Hayles AB, Siekert RG, et al. 1958. Multiple sclerosis in children: A clinical study of 40 cases with onset in childhood. Pediatrics 21:703-709.
27. Ghezzi A, Amato MP, Capobianco M, et al. 2005. Disease-modifying drugs in childhood-juvenile multiple sclerosis: Results of an Italian co-operative study. Mult Scler 11:420-424.
28. Goodin DS, Frohman EM, Garmany GP, et al. 2002. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178.
29. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. 1995. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30-40.
30. Hahn CD, Shroff MM, Blaser SL, et al. 2004. MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort. Neurology 62:806-808.
31. Harris CJ, Halper J. 2004. Multiple Sclerosis: Best Practices in Nursing Care. Disease Management, Pharmacologic Treatment, Nursing Research, 2nd ed. New York: BioScience. p 19.
32. Hauser SL, Dawson DM, Lehrich JR, et al. 1983. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308:173-180.
33. Hynson JL, Kornberg AJ, Coleman LT. 2001. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 56:1308-1312.
34. John GR, Shankar SL, Shafit-Zagardo B, et al. 2002. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8:1115-1121.
35. Johnson RT, Major E. 2003. Infectious demyelinating diseases. In: Lazzarini RA, editor. Myelin Biology and Disorders. St. Louis, MO: Elsevier Academic, pp 953-983.
36. Jones CT. 2003. Childhood autoimmune neurologic diseases of the CNS. Neurol Clin N Am 21:745-764.
37. Kenealy SJ, Pericak-Vance MA, Haines JL. 2003. The genetic epidemiology in MS. J Neuroimmunol 143:7-12.
38. Kupersmith MJ, Kaufman D, Paty DW, et al. 1994. Megadose corticosteroids in multiple sclerosis. Neurology 44:1-4.
39. Kurtzke JF. 1983. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452.
40. Likosky W, Fireman B, Elmore R, et al. 1991. Intense immunosuppression in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 54:1055-1060.
41. Lo AC, Saab CY, Black JA, et al. 2003. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90:3566-3571.
42. Lucchinetti CF, Bruck W, Parisi J, et al. 1999. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122:2279-2295.
43. Lucchinetti CF, Bruck W, Parisi J, et al. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707-717.
44. Lucchinetti CF, Bruck W, Rodriguez M, et al. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274.
45. Matute C, Pérez-Cerdá F. 2005. Multiple sclerosis: Novel perspectives on newly forming lesions. Trends Neurosci 28:173-175.
46. McDonald WI, Compston A, Edan G, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121-127.
47. Merrill JE. 1992. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and CNS acquired immunodeficiency syndrome. J Immunother 12:167-170.
48. Mi S, Miller RH, Lee X, et al. 2005. LINGO-1 negatively regulates myelination by oligodendrocytes. Nature Neurosci 8:745-751.
49. Millefiorini E, Gasperini C, Pozzilli C, et al. 1997. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome. J Neurol 244:153-157.
50. Miller DH, Robb SA, Ormerod IE, et al. 1990. Magnetic resonance imaging of inflammatory and demyelinating white-matter diseases of childhood. Dev Med Child Neurol 32:97-107.
51. Moreau T, Coles A, Wing M, et al. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119:225-237.
52. Neuhaus O, Farina C, Wekerle H, et al. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-708.
53. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. 2002. Stalins as immunomodulators: Comparison with interferon-β1b in MS. Neurology 59:970-971.
54. Neuhaus O, Stüve O, Zamviul S, et al. 2004. Are statins a treatment option for multiple sclerosis? Lancet Neurol 3:369-371.
55. Oldstone MB. 1998. Molecular mimicry and immune-mediated diseases. FASEB J 12:1255-1265.
56. Olek MJ, Dawson DM. 2004. Multiple sclerosis and other inflammatory demyelinating diseases of the CNS. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice: The Neurologic Disorders, 4th ed. Philadelphia, PA: Butterworth-Heinemann. pp 1650-1651.
57. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36: S25-S28.
58. Paolillo A, Coles AJ, Molyneux PD. 1999. Quantitative MRI in patients with secondary progressive multiple sclerosis treated with monoclonal antibody Campath 1H. Neurology 53: 751-757.
59. Polman CH, O'Connor PW, Havrdova E, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910.
60. Polman CH, Reingold SC, Edan G, et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 58:840-846.
61. Poser C. 1983. The diagnosis. In: Scheinberg LC, editor. Multiple Sclerosis: A Guide for Patients and Their Families. New York: Raven, p 31.
62. Poser C. 1995. Onset symptoms in multiple sclerosis. J Neurol Neursurg Psychiatry 58:253-254.
63. Poser C, Paty D, Scheinberg L, et al. 1983. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227-231.
64. Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
65. Rice G. 2004. The genetic epidemiology of multiple sclerosis. In: Miller AE, editor. Continuum: Multiple Sclerosis. Philadelphia, PA: Lippincott. p 28.
66. Rice G, Filippi M, Corni G. 2000. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 54:1145-1155.
67. Robinson WH, Fontoura P, Lee BJ, et al. 2003. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21:1033-1039.
68. Ropper AH. 2006. Selective treatment of multiple sclerosis. N Engl J Med 354:965-967.
69. Rose AS, Kuzma JW, Kurtzke JF, et al. 1970. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo-Final report. Neurology 209:1-59.
70. Rudge P, Koetsier JC, Mertin J, et al. 1989. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 52:559-565.
71. Rudick R, Stuart W, Calabresi P, et al. 2006. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N Engl J Med 354:911-923.
72. Ruggieri M, Polizzi A, Pavone L, et al. 1999. Multiple sclerosis in children under 6 years of age. Neurology 53:478-484.
73. Selcen D, Anlar B, Renda Y. 1996. Multiple sclerosis in childhood: Report of 16 cases. Eur Neurol 36:79-84.
74. Sibley WA, Bamford CR, Clark K. 1985. Clinical viral infection and multiple sclerosis. Lancet 1:1313-1315.
75. Sindern E, Haas J, Stark E, et al. 1992. Early onset MS under the age of 16: Clinical and para-clinical features. Acta Neurol Scand 86:280-284.
76. Sorensen PS, Wanscher B, Jensen CV, et al. 1998. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281.
77. Sorensen TL, Tani M, Jensen J, et al. 1999. Expression of specific chemokines and chemokine receptors in the CNS of multiple sclerosis patients. J Clin Invest 103:807-815.
78. Stonehouse M, Gupte G, Wassmer E, et al. 2003. Acute disseminated encephalomyelitis: Recognition in the hands of general paediatricians. Arch Dis Child 88:122-124.
79. Stüve O, Youssef S, Steinman L, et al. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders, Curr Opin Neurol 16: 393-401.
80. Teitelbaum D, Milo R, Arnon R, et al. 1992. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 89:137-141.
81. Thompson AJ, Kennard C, Swash M, et al. 1989. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39:969-971.
82. Tinoré M, Rovira A, Martinez MJ, et al. 2000. Isolated demyelinating syndromes: Comparison of different MR criteria to predict conversion to clinically-definite multiple sclerosis. Am J Neuroradiol 21:702-706.
83. Valentine MA, Meier KE, Rossie S, et al. 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264:11282-11287.
84. Vasselon T, Detmers PA. 2002. Toll receptors: A central element in innate immune responses. Infect Immun 70:1033-1041.
85. Vollmer T, Key L, Durkalski V, et al. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608.
86. Wang KC, Kim JA, Sivasankaran R, et al. 2002. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420:74-78.
87. Waubant E, Hietpas J, Stewart T, et al. 2001. Interferon β-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 32: 211-213.
88. + channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25:584-591.
89. Wechsler IS. 1922. Statistics of multiple sclerosis; including a study of the infantile, congenital, familial and hereditary forms and the mental and psychic symptoms. Arch Neurol Psychiatry 8:59.
90. Weiner HL, Mackin GA, Orav EJ, et al. 1993. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910-918.
91. Weinshenker BG, O'Brien PC, Petterson TM, et al. 1999. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol 46:878-886.
92. Werner P, Pitt D, Raine CS. 2001. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169-180.
93. Wolinsky JS, Narayana PA. 2002. Magnetic resonance spectroscopy in multiple sclerosis: Window into the diseased brain. Curr Opin Neurol 15:247-251.
94. Youssef S, Stüve O, Patarroyo J, et al. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature 420:78-84.
95. Yudkin PL, Ellison GW, Ghezzi A, et al. 1991. Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051-1055.